Amgen
AMGN
$3.03 (-0.97%)
1D
1W
3M
1Y
5Y
ALL
Amgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine). It focuses on human therapeutics for the treatment of serious illness in the areas of oncology/hematology, cardiovascular disease and neuroscience. Its product candidates in Phase III include Erenumab for episodic migraine, Aranesp for myelodysplastic syndromes, BLINCYTO for acute lymphoblastic leukemia and IMLYGIC for metastatic melanoma.
Open
Prior close
Today's high
Today's low
52 Week high
52 Week low
Zacks Investment Research • 2 days ago • AMGN
5 Stocks Driving Dow's Market-Beating PerformancePRNewsWire • 3 days ago • AMGN
AMGEN TO PRESENT AT THE BANK OF AMERICA MERRILL LYNCH GLOBAL HEALTHCARE CONFERENCEInvestorPlace • 3 days ago • AMGN
7 Weight Loss Drug Stocks Poised for Explosive Growth by 2025InvestorPlace • 3 days ago • AMGN
Sector Superstars: 3 Stocks Generating the Most Buzz on Wall StreetForbes • 4 days ago • AMGN
Will Amgen Stock Continue To See Higher Levels Driven By Its Obesity Injection?Charts and pricing are provided for informational purposes only. The current market data is delayed up to 15 minutes. The accuracy of any market data displayed is not guaranteed.